Actuate Therapeutics Inc (ACTU) - News Archive

In the ever-evolving landscape of oncology therapeutics, Actuate Therapeutics, Inc. (NASDAQ: ACTU) stands at the forefront, committed to addressing the formidable challenges posed by high-impact, difficult-to-treat canc...

Advancements in Pediatric OncologyRecent advancements in the field of pediatric oncology have captured the attention of researchers, practitioners, and investors alike. Actuate Therapeutics has made significant strides...

In a significant development in the fight against one of the deadliest forms of cancer, Actuate Therapeutics, Inc. (NASDAQ: ACTU) has announced positive interim results from its ongoing randomized Phase 2 trial investig...

In a significant milestone for Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company dedicated to developing therapies for high-impact, difficult-to-treat cancers, the company is poised t...

Actuate Therapeutics Unveils New Insights into Combating One of the Most Aggressive Cancers At the AACR Special Conference on Advances in Pancreatic Cancer Research, Actuate Therapeutics, Inc. revealed preliminary findi...

In a significant advancement in the treatment of soft tissue sarcomas (STS), Actuate Therapeutics, Inc. a clinical-stage biopharmaceutical company, announced on September 11, 2024, that the U.S. Food and Drug Administra...

In a noteworthy update that has reverberated across the biopharmaceutical world, Actuate Therapeutics, Inc. listed on NASDAQ under the ticker ACTU has provided a glimmer of hope for patients battling one of the most cha...

Actuate Therapeutics to Ring the Nasdaq Opening Bell on August 23, 2024, Marking a New Chapter in Biopharmaceutical Innovation CHICAGO and FORT WORTH, Texas In a significant milestone for the biopharmaceutical community...